Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Experience with ifosfamide in paediatric tumours.

Literature DB >> 2758568

Experience with ifosfamide in paediatric tumours.

Abstract

Ifosfamide, alone or in combination, is used in a variety of childhood tumours. Soft-tissue sarcomas are especially sensitive, with a 78% actuarial survival. Hyperaminoaciduria and a brief transient decrease in the plasma level of certain amino acids are the earliest signs of tubular toxicity.

Entities: Chemical Disease

Mesh：

Substances：
Ifosfamide

Year: 1989 PMID： 2758568 DOI： 10.1007/BF00253235

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

5 in total

1. Ifosfamide, mesna and vincristine in paediatric oncology.

Authors: J de Kraker; P A Voûte
Journal: Cancer Treat Rev Date: 1983-09 Impact factor: 12.111

2. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

Authors: M P Goren; R K Wright; C B Pratt; M E Horowitz; R K Dodge; M J Viar; E H Kovnar
Journal: Cancer Res Date: 1987-03-01 Impact factor: 12.701

3. Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group.

Authors: S J Kellie; J De Kraker; J S Lilleyman; A Bowman; J Pritchard
Journal: Eur J Cancer Clin Oncol Date: 1988-05

Experience with ifosfamide in paediatric tumours.

1. Ifosfamide, mesna and vincristine in paediatric oncology.

2. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

3. Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group.

4. Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group.

5. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

1. Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.

2. Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.

3. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Review 4. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

5. Current therapeutic strategies and novel approaches in osteosarcoma.